Review Article| Volume 37, ISSUE 1, P117-132, February 2023

Biology and Treatment of HER2-Low Breast Cancer

  • Eleonora Nicolò
    Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti, 435, 20141 Milano MI, Italy

    Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
    Search for articles by this author
  • Paolo Tarantino
    Corresponding author. Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215.
    Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti, 435, 20141 Milano MI, Italy

    Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

    Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA

    Harvard Medical School, Boston, USA
    Search for articles by this author
  • Giuseppe Curigliano
    Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti, 435, 20141 Milano MI, Italy

    Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
    Search for articles by this author


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Hematology/Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gutierrez C.
        • Schiff R.
        HER2: biology, detection, and clinical implications.
        Arch Pathol Lab Med. 2011; 135: 55-62
        • Martínez-Sáez O.
        • Prat A.
        Current and Future Management of HER2-Positive Metastatic Breast Cancer.
        JCO Oncol Pract. 2021; 17: 594-604
        • Wolff A.C.
        • Hammond M.E.H.
        • Allison K.H.
        • et al.
        Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
        J Clin Oncol. 2018; 36: 2105-2122
        • Fehrenbacher L.
        • Cecchini R.S.
        • Geyer Jr., C.E.
        • et al.
        NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+.
        J Clin Oncol. 2020; 38: 444-453
        • Gianni L.
        • Lladó A.
        • Bianchi G.
        • et al.
        Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastat.
        J Clin Oncol. 2010; 28: 1131-1137
        • Tarantino P.
        • Hamilton E.
        • Tolaney S.M.
        • et al.
        HER2-Low Breast Cancer: Pathological and Clinical Landscape.
        J Clin Oncol. 2020; 38: 1951-1962
        • Osborne C.K.
        • Shou J.
        • Massarweh S.
        • et al.
        Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
        Clin Cancer Res. 2005; 11 (Available at:): 865s-870s
        • Schettini F.
        • Chic N.
        • Brasó-Maristany F.
        • et al.
        Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
        npj Breast Cancer. 2021; 7: 1
        • Denkert C.
        • Seither F.
        • Schneeweiss A.
        • et al.
        Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
        Lancet Oncol. 2021; 22: 1151-1161
        • Miglietta F.
        • Griguolo G.
        • Bottosso M.
        • et al.
        Evolution of HER2-low expression from primary to recurrent breast cancer.
        npj Breast Cancer. 2021; 7: 137
        • Agostinetto E.
        • Rediti M.
        • Fimereli D.
        • et al.
        HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.
        Cancers (Basel). 2021; 13: 2824
        • Won H.S.
        • Ahn J.
        • Kim Y.
        • et al.
        Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society.
        Breast Cancer Res. 2022; 24: 22
        • Tan R.S.Y.C.
        • Ong W.S.
        • Lee K.H.
        • et al.
        HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
        BMC Med. 2022; 20: 105
        • Tarantino P.
        • Jin Q.
        • Tayob N.
        • et al.
        1MO - Prognostic and biologic significance of HER2-low expression in early breast cancer.
        Ann Oncol. 2022; 33: S124
        • Frenel J.S.
        • Lusque A.
        • Mailliez A.
        • et al.
        291P HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting.
        Ann Oncol. 2021; 32: S491
        • Hein A.
        • Hartkopf A.D.
        • Emons J.
        • et al.
        Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.
        Eur J Cancer. 2021; 155: 1-12
        • Gampenrieder S.P.
        • Rinnerthaler G.
        • Tinchon C.
        • et al.
        Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
        Breast Cancer Res. 2021; 23: 112
        • Lambein K.
        • Van Bockstal M.
        • Vandemaele L.
        • et al.
        Distinguishing Score 0 From Score 1+ in HER2 Immunohistochemistry-Negative Breast Cancer.
        Am J Clin Pathol. 2013; 140: 561-566
        • Fernandez A.I.
        • Liu M.
        • Bellizzi A.
        • et al.
        Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.
        JAMA Oncol. 2022; 8: 1
        • Tarantino P.
        • Gandini S.
        • Nicolò E.
        • et al.
        Evolution of low HER2 expression between early and advanced-stage breast cancer.
        Eur J Cancer. 2022; 163: 35-43
        • Miglietta F.
        • Griguolo G.
        • Bottosso M.
        • et al.
        HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment.
        npj Breast Cancer. 2022; 8: 66
        • Paik S.
        • Kim C.
        • Wolmark N.
        HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer.
        N Engl J Med. 2008; 358: 1409-1411
        • Perez E.A.
        • Romond E.H.
        • Suman V.J.
        • et al.
        Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831.
        J Clin Oncol. 2014; 32: 3744-3752
        • Bang Y.J.
        • Giaccone G.
        • Im S.A.
        • et al.
        First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.
        Ann Oncol. 2017; 28: 855-861
        • Krop I.E.
        • LoRusso P.
        • Miller K.D.
        • et al.
        A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine.
        J Clin Oncol. 2012; 30: 3234-3241
        • Burris H.A.
        • Rugo H.S.
        • Vukelja S.J.
        • et al.
        Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy.
        J Clin Oncol. 2011; 29: 398-405
        • Denkert C.
        • Lambertini C.
        • Fasching P.A.
        • et al.
        Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
        J Clin Oncol. 2020; 38: 502
        • Yazaki S.
        • Hashimoto J.
        • Ogita S.
        • et al.
        Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a ret.
        Anticancer Drugs. 2020; 31: 973-978
        • Filho O.M.
        • Viale G.
        • Stein S.
        • et al.
        Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.
        Cancer Discov. 2021; 11: 2474-2487
        • Modi S.
        • Park H.
        • Murthy R.K.
        • et al.
        Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
        J Clin Oncol. 2020; 19: 02318
        • Modi S.
        • Jacot W.
        • Yamashita T.
        • et al.
        Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
        N Engl J Med. 2022; 387: 9-20
        • Diéras V.
        • Deluche E.
        • Lusque A.
        • et al.
        Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY).
        Cancer Res. 2022; 82: PD8-02
        • Nicolò E.
        • Giugliano F.
        • Ascione L.
        • et al.
        Combining Antibody-drug Conjugates with Immunotherapy in Solid Tumors: Current Landscape and Future Perspectives.
        Cancer Treat Rev. 2022; 106: 102395
        • Iwata T.N.
        • Ishii C.
        • Ishida S.
        • et al.
        A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model.
        Mol Cancer Ther. 2018; 17: 1494-1503
        • Schmid P.
        • Im S.A.
        • Armstrong A.
        • et al.
        BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).
        J Clin Oncol. 2021; 39: 1023
        • Hamilton E.P.
        • Shapiro C.L.
        • Boni V.
        • et al.
        162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer.
        Ann Oncol. 2022; 33: S196
        • van der Lee M.M.C.
        • Groothuis P.G.
        • Ubink R.
        • et al.
        The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.
        Mol Cancer Ther. 2015; 14: 692-703
        • Banerji U.
        • van Herpen C.M.L.
        • Saura C.
        • et al.
        Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
        Lancet Oncol. 2019; 20: 1124-1135
        • Wang J.
        • Liu Y.
        • Zhang Q.
        • et al.
        RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.
        J Clin Oncol. 2021; 39: 1022
        • Pistilli B.
        • Wildiers H.
        • Hamilton E.P.
        • et al.
        Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).
        J Clin Oncol. 2020; 38: 1037
        • Wermke M.
        • Alt J.
        • Kauh J.
        • et al.
        Preliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers.
        Ann Oncol. 2018; 29 (suppl 8; abstr 1147P): viii400-viii441
        • Cardoso F.
        • Dirix L.
        • Conte P.
        • et al.
        Abstract P3-14-21: Phase II Study of Single Agent Trifunctional Antibody Ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 Low Expressing Hormone-Refractory Advanced Breast Cancer Patients (ABC).
        in: Poster session abstracts. American Association for Cancer Research, 2010: 14-21
        • Meric-Bernstam F.
        • Beeram M.
        • Mayordomo J.I.
        • et al.
        Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.
        J Clin Oncol. 2018; 36: 2500
        • Mittendorf E.A.
        • Clifton G.T.
        • Holmes J.P.
        • et al.
        Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.
        Ann Oncol. 2014; 25: 1735-1742
        • Mittendorf E.A.
        • Lu B.
        • Melisko M.
        • et al.
        Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.
        Clin Cancer Res. 2019; 25: 4248-4254
        • Gall V.A.
        • Philips A.V.
        • Qiao N.
        • et al.
        Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
        Cancer Res. 2017; 77: 5374-5383
        • Clifton G.T.
        • Hale D.
        • Vreeland T.J.
        • et al.
        Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.
        Clin Cancer Res. 2020; 26: 2515-2523
        • Brown T.A.
        • Mittendorf E.A.
        • Hale D.F.
        • et al.
        Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
        Breast Cancer Res Treat. 2020; 181: 391-401
        • Drago J.Z.
        • Modi S.
        • Chandarlapaty S.
        Unlocking the potential of antibody–drug conjugates for cancer therapy.
        Nat Rev Clin Oncol. 2021; 18: 327-344
        • Giugliano F.
        • Corti C.
        • Tarantino P.
        • et al.
        Bystander effect of antibody–drug conjugates: fact or fiction?.
        Curr Oncol Rep. 2022; 24: 809-817
        • Bardia A.
        • Hurvitz S.A.
        • Tolaney S.M.
        • et al.
        Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
        N Engl J Med. 2021; 384: 1529-1541